Free Trial

Atossa Genetics (ATOS) Competitors

Atossa Genetics logo
$0.86 -0.02 (-2.76%)
Closing price 07/24/2025 04:00 PM Eastern
Extended Trading
$0.90 +0.03 (+3.84%)
As of 04:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ATOS vs. CGEM, MBX, RZLT, KMDA, TERN, RGNX, SVRA, TECX, FULC, and SLDB

Should you be buying Atossa Genetics stock or one of its competitors? The main competitors of Atossa Genetics include Cullinan Therapeutics (CGEM), MBX Biosciences (MBX), Rezolute (RZLT), Kamada (KMDA), Terns Pharmaceuticals (TERN), REGENXBIO (RGNX), Savara (SVRA), Tectonic Therapeutic (TECX), Fulcrum Therapeutics (FULC), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry.

Atossa Genetics vs. Its Competitors

Cullinan Therapeutics (NASDAQ:CGEM) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

Cullinan Therapeutics has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Comparatively, Atossa Genetics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

In the previous week, Cullinan Therapeutics and Cullinan Therapeutics both had 1 articles in the media. Atossa Genetics' average media sentiment score of 1.89 beat Cullinan Therapeutics' score of 1.87 indicating that Atossa Genetics is being referred to more favorably in the news media.

Company Overall Sentiment
Cullinan Therapeutics Very Positive
Atossa Genetics Very Positive

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are held by institutional investors. 7.2% of Cullinan Therapeutics shares are held by insiders. Comparatively, 7.6% of Atossa Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cullinan Therapeutics' return on equity of -29.47% beat Atossa Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cullinan TherapeuticsN/A -29.47% -28.19%
Atossa Genetics N/A -33.90%-31.53%

Cullinan Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 260.14%. Atossa Genetics has a consensus price target of $6.17, suggesting a potential upside of 615.47%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Cullinan Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cullinan Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Atossa Genetics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

Atossa Genetics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan TherapeuticsN/AN/A-$167.38M-$2.91-2.86
Atossa GeneticsN/AN/A-$25.50M-$0.21-4.10

Summary

Atossa Genetics beats Cullinan Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Atossa Genetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATOS vs. The Competition

MetricAtossa GeneticsMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$114.50M$6.94B$5.73B$9.47B
Dividend YieldN/A1.28%4.60%3.99%
P/E Ratio-4.1025.4327.9319.95
Price / SalesN/A49.70438.49101.76
Price / CashN/A20.6736.5558.97
Price / Book1.514.728.655.90
Net Income-$25.50M$176.14M$3.24B$258.42M
7 Day Performance2.38%3.35%3.71%2.12%
1 Month Performance0.01%3.91%10.34%12.46%
1 Year Performance-38.87%8.55%34.54%19.56%

Atossa Genetics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATOS
Atossa Genetics
2.3283 of 5 stars
$0.86
-2.8%
$6.17
+615.5%
-38.4%$114.50MN/A-4.108
CGEM
Cullinan Therapeutics
1.4507 of 5 stars
$7.87
+2.2%
$30.00
+281.2%
-59.0%$464.41MN/A-2.7030Positive News
MBX
MBX Biosciences
2.2426 of 5 stars
$13.87
+6.4%
$37.50
+170.4%
N/A$463.59MN/A0.0036
RZLT
Rezolute
2.6388 of 5 stars
$5.32
+1.1%
$11.83
+122.4%
+26.5%$454.97MN/A-4.6340
KMDA
Kamada
3.326 of 5 stars
$7.78
+0.4%
$13.00
+67.1%
+33.7%$447.39M$167.24M26.83360
TERN
Terns Pharmaceuticals
3.6241 of 5 stars
$5.11
+4.3%
$15.63
+205.8%
-30.1%$446.31MN/A-4.6940Positive News
RGNX
REGENXBIO
4.2711 of 5 stars
$8.70
+0.2%
$31.63
+263.5%
-33.1%$436.39M$83.33M-2.80370
SVRA
Savara
1.9502 of 5 stars
$2.51
+5.0%
$5.60
+123.1%
-43.5%$433.83MN/A-5.2320Positive News
TECX
Tectonic Therapeutic
2.634 of 5 stars
$23.12
+2.1%
$83.60
+261.6%
+31.1%$431.72MN/A-3.16120
FULC
Fulcrum Therapeutics
0.6003 of 5 stars
$7.90
+0.9%
$6.29
-20.4%
-8.6%$426.44M$80M-112.84100Upcoming Earnings
SLDB
Solid Biosciences
3.2936 of 5 stars
$5.47
+4.0%
$15.10
+176.1%
-24.4%$423.98M$8.09M-1.83100

Related Companies and Tools


This page (NASDAQ:ATOS) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners